Patents by Inventor Wenqing Yao

Wenqing Yao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20240383889
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: December 19, 2023
    Publication date: November 21, 2024
    Inventors: Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20240368152
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: February 9, 2024
    Publication date: November 7, 2024
    Inventors: Qinda YE, Matthew MCCAMMANT, Rocco POLICARPO, Artem SHVARTSBART, Wenyu ZHU, Jeremy ROACH, Gia HOANG, Bin HU, Gencheng LI, Robert SUSICK, Padmaja POLAM, Fenglei ZHANG, Chao QI, Xiaozhao WANG, Wenqing YAO, Alexander Sokolsky, Haolin YIN, Le ZHAO, Peter Carlsen
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20240360140
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: March 28, 2024
    Publication date: October 31, 2024
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • Heteroaryl amide compounds as sting activators
    Patent number: 12129267
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: October 29, 2024
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 12122767
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: October 22, 2024
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Hai Fen Ye, Wenqing Yao
  • VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20240343742
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: April 23, 2024
    Publication date: October 17, 2024
    Inventors: Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao
  • IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20240309008
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: May 22, 2024
    Publication date: September 19, 2024
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 12083124
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: September 10, 2024
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Imidazotriazines and imidazopyrimidines as kinase inhibitors
    Patent number: 12084449
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: September 10, 2024
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Imidazole and triazole KRAS inhibitors
    Patent number: 12077539
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: September 3, 2024
    Assignee: Incyte Corporation
    Inventors: Chao Qi, Xiaozhao Wang, Wenqing Yao
  • PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20240287059
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
    Type: Application
    Filed: September 8, 2023
    Publication date: August 29, 2024
    Inventors: Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
  • TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
    Publication number: 20240287086
    Abstract: The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: December 19, 2023
    Publication date: August 29, 2024
    Inventors: Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao
  • CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
    Patent number: 12060433
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: August 13, 2024
    Assignee: Incyte Corporation
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
    Publication number: 20240246974
    Abstract: The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: October 20, 2023
    Publication date: July 25, 2024
    Inventors: Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
  • Hetero-tricyclic compounds as inhibitors of KRAS
    Patent number: 12030883
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu
  • Pyrazoloquinoline KRAS inhibitors
    Patent number: 12030884
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Wenyu Zhu, Xiaozhao Wang, Wenqing Yao
  • Imidazopyridazine and imidazopyridine compounds and uses thereof
    Patent number: 12030889
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20240216377
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: October 3, 2023
    Publication date: July 4, 2024
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 12012409
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: June 18, 2024
    Assignee: Incyte Corporation
    Inventors: Jeremy Roach, Artem Shvartsbart, Michael Witten, Wenqing Yao
  • Vinyl imidazole compounds as inhibitors of KRAS
    Patent number: 11999752
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: June 4, 2024
    Assignee: Incyte Corporation
    Inventors: Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao